Shire bid marks Takeda's latest - and biggest - push for global status

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Shire bid marks Takeda's latest - and biggest - push for global status

Bristol-Myers Squibb (BMY) Reports Clinical Trial Collaboration with Advantagene Inc.

April 27, 2018 7:16 AM EDT

Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of Advantagenes investigational Gene Mediated Cytotoxic Immunotherapy (GMCI, aglatimagene besadenovec + valacyclovir), in combination with Bristol-Myers Squibbs programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), in newly diagnosed malignant glioma patients receiving standard of care (SOC) surgery and radiation with or without temozolomide. This study is being conducted in collaboration with leading... More